NervGen Pharma Corp. (NGEN) Fair Value 2026

NGEN · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.4 /10

32 fundamental signals · 6 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, NervGen Pharma Corp. (NGEN) trades at $1.69, approximately 163% above CirclFi’s Bayesian DCF fair value of $0.64. QOC: 3.4/10. 6/13 models active.

Key Facts

Ticker
NGEN
Price
$1.69
Quality Score
3.4/10
Value Trap Risk
—/100
Models Active
6/13
Last Updated
Strength: First Chicago suggests +228.1% upside with 10% confidence
Risk: Below-average Quality Score of 3.4/10 signals weak fundamentals

Is NervGen Pharma Corp. (NGEN) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, NervGen Pharma Corp. (NGEN) appears fairly valued as of : the median of 6 independent fair value estimates is $1.72, within 2.0% of the current price of $1.69. Estimates range from $0.09 to $5.54. NGEN scores 3.4/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy NervGen Pharma Corp. Stock in 2026? →

Valuation Matrix

6 Intrinsic Value Models vs. Current Price ($1.69)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.64 -61.9%
CUCE Ensemble
Low Conviction
 $1.29 -23.7%
First Chicago
Low Conviction
 $5.54 +228.1%

Unlock the Full Matrix

Access 3 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is NervGen Pharma Corp. (NGEN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, NervGen Pharma Corp. presents a highly debated valuation profile at its current price of $1.69. The composite intrinsic value is estimated at $2.07 (+22.6% average upside), masking a wide model spread between the 3 bullish models and 3 bearish models. Model dispersion is worth noting: First Chicago targets $5.54 (+228.1%), versus Dynamic NAV at $0.09 (-94.7%). This +322.7% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About NGEN?

6 of 13 models are currently active for NGEN. Of these, 3 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates NGEN's intrinsic value at $0.64, implying -61.9% downside from the current price. See which stocks rank higher →

How Does NGEN Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, NGEN ranks #376 by Quality of Company score. CirclFi's QOC score of 3.4/10 evaluates 32 fundamental signals. A score of 3.4 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For NervGen Pharma Corp., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.

Is NGEN a Value Trap?

The Value Trap algorithm is not active for NGEN. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for NervGen Pharma Corp.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, NervGen Pharma Corp. scores 3.4 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +322.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NGEN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NGEN's 6 active models, average confidence is 15%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy NervGen Pharma Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About NervGen Pharma Corp.

What is NervGen Pharma Corp.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, NervGen Pharma Corp. (NGEN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.64. The Quality of Company score is 3.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NGEN overvalued or undervalued right now?

At $1.69, 3 of 6 active models suggest NGEN may be undervalued, while 3 indicate potential overvaluation. The median of all 6 fair value estimates is $1.72, within 2.0% of the current price of $1.69 — a consensus view that NGEN is fairly valued. The assessment depends on which methodology best fits NervGen Pharma Corp.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 3.4 mean for NGEN?

NervGen Pharma Corp.'s QOC of 3.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NGEN?

CirclFi analyzes NGEN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Is NGEN a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for NGEN at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 6-model valuation engine, NervGen Pharma Corp. (NGEN) has a median fair value of $1.72 — within 2.0% of the current price of $1.69 — as of 2026-07-15.” Source: circlfi.com/stock/NGEN/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on NGEN.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access